Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

NCT06887192 is registered in ClinicalTrials.gov with MapLight Therapeutics as lead sponsor.

NCT NCT06887192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06887192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Lead sponsor
MapLight Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
August 15, 2025
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis associated with alzheimer's disease